Ignite Creation Date:
2024-05-06 @ 12:53 PM
Last Modification Date:
2024-10-26 @ 1:05 PM
Study NCT ID:
NCT03875235
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-16
First Post:
2019-03-13
Brief Title:
Durvalumab or Placebo in Combination With GemcitabineCisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Organization Data
Organization:
AstraZeneca
Class:
INDUSTRY
Study ID:
D933AC00001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
AstraZeneca
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None